The global blood screening market size was USD 3.08 billion in 2023, calculated at USD 3.44 billion in 2024 and is projected to surpass around USD 10.41 billion by 2034, expanding at a CAGR of 11.7% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Blood Screening Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Blood Screening Market, by Technology, 2024-2034
8.1.1. Nucleic Acid Amplification Test (NAT)
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. ELISA
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Next Generation Sequencing
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Western Blotting
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Blood Screening Market, by Product, 2024-2034
9.1.1. Reagent
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Instrument
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.2. Market Revenue and Forecast, by Product (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Product (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.2. Market Revenue and Forecast, by Product (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Product (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Product (2021-2034)
11.1. Instrument
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Roche Diagnostics
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bio-Rad Laboratories, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Thermo Fisher Scientific Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Ortho Clinical Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Grifols
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. BioMérieux SA
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Siemens Healthineers
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Becton, Dickinson and Company (BD)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Quest Diagnostics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample